Preliminary outcomes of boron neutron capture therapy for head and neck cancers as a treatment covered by public health insurance system in Japan: Real-world experiences over a 2-year period.
boron
boron neutron capture therapy
head and neck cancer
radiation therapy
re‐irradiation
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
16
04
2024
received:
05
01
2024
accepted:
28
04
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
ppublish
Résumé
Since June 2020, boron neutron capture therapy (BNCT) has been a health care service covered by health insurance in Japan to treat locally advanced or recurrent unresectable head and neck cancers. Therefore, we aimed to assess the clinical outcomes of BNCT as a health insurance treatment and explore its role among the standard treatment modalities for head and neck cancers. We retrospectively analyzed data from patients who were treated using BNCT at Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, between June 2020 and May 2022. We assessed objective response rates based on the Response Evaluation Criteria in Solid Tumors version 1.1, and adverse events based on the Common Terminology Criteria for Adverse Events, version 5.0. Additionally, we conducted a survival analysis and explored the factors that contributed to the treatment results. Sixty-nine patients (72 treatments) were included in the study, with a median observation period of 15 months. The objective response rate was 80.5%, and the 1-year locoregional control, progression-free survival, and overall survival rates were 57.1% (95% confidence interval [CI]: 43.9%-68.3%), 42.2% (95% CI: 30.1%-53.8%), and 75.4% (95% CI: 62.5%-84.5%), respectively. Locoregional control was significantly longer in patients with earlier TNM staging and no history of chemotherapy. BNCT may be an effective treatment option for locally advanced or recurrent unresectable head and neck cancers with no other definitive therapies. If definitive surgery or radiation therapy are not feasible, BNCT should be considered at early disease stages.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e7250Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP23K14878
Informations de copyright
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Locher GL. Biological effects and therapeutic possibilities of neutron. Am J Roentgenol. 1936;36:1‐3.
Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat Res. 1999;151:1‐18.
INTERNATIONAL ATOMIC ENERGY AGENCY. Advances in Boron Neutron Capture Therapy. IAEA; 2023.
Ali F, Hosmane NS, Zhu Y. Boron chemistry for medical applications. Molecules. 2020;25:828.
Mishima Y, Honda C, Ichihashi M, et al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma‐seeking 10B‐compound. Lancet. 1989;2:388‐389.
Wongthai P, Hagiwara K, Miyoshi Y, et al. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0, +, LAT1 and LAT2. Cancer Sci. 2015;106:279‐286.
Hayashi K, Anzai N. Novel therapeutic approaches targeting L‐type amino acid transporters for cancer treatment. World J Gastrointest Oncol. 2017;9:21‐29.
Morris GM, Coderre JA, Hopewell JW, Micca PL, Rezvani M. Response of rat skin to boron neutron capture therapy with p‐boronophenylalanine or borocaptate sodium. Radiother Oncol. 1994;32:144‐153.
Kato I, Ono K, Sakurai Y, et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot. 2004;61:1069‐1073.
Kankaanranta L, Seppälä T, Koivunoro H, et al. Boron neutron capture therapy in the treatment of locally recurred head‐and‐neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2012;82:e67‐e75.
Wang LW, Chen YW, Ho CY, et al. Fractionated boron neutron capture therapy in locally recurrent head and neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys. 2016;95:396‐403.
Suzuki M, Kato I, Aihara T, et al. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res. 2014;55:146‐153.
Aihara T, Morita N, Kamitani N, et al. BNCT for advanced or recurrent head and neck cancer. Appl Radiat Isot. 2014;88:12‐15.
Tanaka H, Sakurai Y, Suzuki M, et al. Characteristics comparison between a cyclotron‐based neutron source and KUR‐HWNIF for boron neutron capture therapy. Nucl Inst Methods Phys Res B. 2009;267:1970‐1977.
Hirose K, Konno A, Hiratsuka J, et al. Boron neutron capture therapy using cyclotron‐based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): an open‐label phase II trial. Radiother Oncol. 2021;155:182‐187.
Aihara T, Hiratsuka J, Morita N, et al. First clinical case of boron neutron capture therapy for head and malignancies using 18F‐BPA PET. Head Neck. 2006;28:850‐855.
Igaki H, Nakamura S, Kurihara H, et al. Comparison of 18FBPA uptake with 18FDG uptake in cancer patients. Appl Radiat Isot. 2020;157:109019.
Hiratsuka J, Fukuda H, Kobayashi T, et al. The relative biological effectiveness of 10B‐neutron capture therapy for early skin reaction in the hamster. Radiat Res. 1991;128:186‐191.
Coderre JA, Makar MS, Micca PL, et al. Derivations of relative biological effectiveness for the high‐let radiations produced during boron neutron capture irradiations of the 9l rat gliosarcoma in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1993;27:1121‐1129.
Fukuda H, Hiratsuka J, Honda C, et al. Boron neutron capture therapy of malignant melanoma using 10B‐paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin. Radiat Res. 1994;138:435‐442.
Coderre JA, Morris GM, Kalef‐Ezra J, et al. The effects of boron neutron capture irradiation on oral mucosa: evaluation using a rat tongue model. Radiat Res. 1999;152:113‐118.
Teruhito A, Junichi H, Masaaki H, et al. BNCT for head and neck cancer; current and future (in Japanese). BIO Clinica. 2019;34:433‐440.
Aihara T, Hiratsuka J, Ishikawa H, et al. Fatal carotid blowout syndrome after BNCT for head and neck cancers. Appl Radiat Isot. 2015;106:202‐206.
Hu N, Tanaka H, Kakino R, et al. Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against an independent Monte Carlo dose calculation system. Radiat Oncol. 2021;16:243.
Ono K. Two‐step rate infusion of 4‐borono‐l‐phenylalanine (BPA) solution in BPA‐BNCT (Ono's method). Advances in Boron Neutron Capture Therapy. International Atomic Energy Agency; 2023.
Hu N, Tanaka H, Akita K, et al. Accelerator based epithermal neutron source for clinical boron neutron capture therapy. J Neutron Res. 2023;24:359‐366.
Davidson‐Pilon C. Lifelines: survival analysis in python. J Open Source Softw. 2019;4:1317.
Ono K, Masunaga SI, Kinashi Y, et al. Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy. Int J Radiat Oncol Biol Phys. 1996;34:1081‐1086.
Yokoyama K, Miyatake SI, Kajimoto Y, et al. Analysis of boron distribution in vivo for boron neutron capture therapy using two different boron compounds by secondary ion mass spectrometry. Radiat Res. 2007;167:102‐109.
Masunaga SI, Sanada Y, Tano K, et al. An attempt to improve the therapeutic effect of boron neutron capture therapy using commonly employed 10B‐carriers based on analytical studies on the correlation among quiescent tumor cell characteristics, tumor heterogeneity and cancer stemness. J Radiat Res. 2020;61:876‐885.
Takeno S, Tanaka H, Ono K, Mizowaki T, Suzuki M. Analysis of boron neutron capture reaction sensitivity using Monte Carlo simulation and proposal of a new dosimetry index in boron neutron capture therapy. J Radiat Res. 2022;63:780‐791.